Introduction:Microsatellite instability (MSI) testing and tumor mutational burden (TMB) are genomic biomarkers used to identify patients who are likely to benefit from immune checkpoint inhibitors. Pembrolizumab was recently approved by the Food and Drug Administration for use in TMB-high (TMB-H) ...
Immune checkpoint inhibitors have been approved in the USA for tumours exhibiting mismatch repair deficiency (dMMR), microsatellite instability (MSI), or high tumour mutational burden (TMB), with regulatory and reimbursement applications in multiple othe
百度试题 结果1 题目研究表明,以下符合胆囊癌免疫治疗的指标是( ) A. TMB-Low B. MSI-High C. CEA-Low D. AFP-High 相关知识点: 试题来源: 解析 B 反馈 收藏
MSI-H and TMB-high patients harbored more mismatch repair genes, such as MSH2, homologous recombination-related genes, such as ATR and BRCA2, and other genes including BRAF, KMT2D, and SMARCA4. None of the 6 MSI-H patients who received chemotherapy achieved a cl...
Overall, TMB-H was more common in high-grade NENs compared to low/int-grade NENs [17% (N=147) vs. 6.2% (N=31), P<0.001]. This was also observed in lung NENs [high-grade 19% (N=135) v low/int grade 10% (N=19), P=0.006], with other organ site analyses limited by ...
1051P Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitorsdoi:10.1016/j.annonc.2024.08.1109A. ItalianoJ.C. TrentG. SledgeJ. XiuE.S. AntonarakisG. D'AmatoD. Hsieh